Contact Supplier

Contact Supplier

To get in touch with Polypharma Technologies & Sciences GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    Polypharma antiemetic drug dossiers

    products-servicesPolypharma Technologies & Sciences GmbH
    March 7th 2023

    Polypharma Technologies & Sciences GmbH (Polypharma) can provide support for development of antiemetic medicines used to alleviate nausea from a variety of causes.

    These antiemetic drug dossiers can be used to empower potential producers across the Middle East and North Africa (MENA) region who are seeking fast track market-ready antiemetic drugs in oral solid dose and other forms for oncology, motion sickness, pregnancy and other applications.

    Antiemetic medicines

    Antiemetic is the term used to describe a medicine that eases nausea or vomiting, provided either on a prescription or over the counter (OTC) basis.

    Since feelings of nausea result from a variety of complex physiological processes, a wide range of anti-emetic drugs have been developed to target a range of causes, listed under different overall applications and categories. These include motion sickness (antihistamines, etc.), viral or bacterial infections, such as stomach flu, ‘morning sickness’ in pregnancy, the after effects of surgery or side-effects from radiotherapy or chemotherapy in oncology.

    Most anti-emetic medications work by blocking the neurotransmitter chemical messengers that send information to the brain and trigger vomiting responses.

    Polypharma antiemetic drug dossiers

    Polypharma’s extensive portfolio of generic human medicines available as pre-prepared dossiers includes a number of significant antiemetic drugs in its Gastroenterology and Hepatology categories. These include:

    • Metoclopramid: medication used to treat problems in the stomach and oesophagus that lead to nausea and vomiting. This drug can also alleviate delayed stomach emptying, and gastroesophageal reflux disease. It is also indicated as a treatment for migraine.
    • Ondansetron: specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastro-intestinal tract and in the CNS indicated for OSD or injected treatment of emetogenic chemotherapy or radiotherapy, as well as prevention of postoperative nausea and vomiting.
    • Domperidon: dopamine antagonist medication (brand name Motilium, etc.,) used in tablet or liquid form to treat nausea and vomiting and gastrointestinal problems such as gastroparesis. It raises the level of prolactin in the human body and can be used to induce and promote breast milk production
    • Dexamethasone: glucocorticoid medication used to treat nausea and vomiting along with a wide range of other conditions, including rheumatic problems, skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye inflammation, autoimmune conditions, and In hospitals as a treatment for severe COVID-19 cases.

    The above list refers only to those antiemetics already subject of fully-developed drug dossiers. Polypharma’s Research & Development pipeline also contains other antiemetics in mid- or late-stage development. These include Skopolamin, Alizapride chlorhydrate, Aprépitant, Dropéridol, Granisétron, and Nétupitant.

    Polypharma is also able to develop other antiemetic dossiers on request and after having carried out a specific feasibility study on the substance.


    Click on Polypharma human medicine dossiers for further information.
    Click on Generic drug dossier development  for further information.

    Polypharma antiemetic drug dossiers

    Polypharma’s wide portfolio of market ready generic antiemetic drug dossiers are offered in pre-developed technical form ready for human medicines application across the MENA region.

    Contact Polypharma Technologies & Sciences GmbH

    Simply fill out the form below to contact Polypharma Technologies & Sciences GmbH now.

    Send Polypharma Technologies & Sciences GmbH a Message

      View Articles by Polypharma Technologies & Sciences GmbH